American Trial Using Tranexamic Acid in Thrombocytopenia



Status:Recruiting
Conditions:Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - Any
Updated:1/3/2019
Start Date:June 2016
End Date:June 2020
Contact:Heather Herren
Email:hherren@uw.edu
Phone:800-332-0586

Use our guide to learn which trials are right for you!

American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT)

The purpose of this study is to evaluate the usefulness of antifibrinolytic therapy with
tranexamic acid (TXA) in preventing bleeding in patients who are thrombocytopenic due to
primary bone marrow disorders or chemotherapy, immunotherapy and/or radiation therapy.

The purpose of this study is to conduct a prospective, randomized, blinded, placebo
controlled trial to evaluate the usefulness of antifibrinolytic therapy with tranexamic acid
in preventing bleeding in patients who are thrombocytopenic due to primary bone marrow
disorders or chemotherapy, immunotherapy and/or radiation therapy. The results of this study
will change practice by providing evidence as to whether or not TXA is effective and safe
treatment when used as an adjunct to platelet transfusion therapy in the thrombocytopenic
patient.

Inclusion criteria (all must be met):

- Must be ≥ 18 years of age

- Confirmed diagnosis of a hematologic malignancy or aplasia

- Undergoing or planned chemotherapy, immunotherapy, or hematopoietic stem cell
transplantation

- Anticipated to have hypoproliferative thrombocytopenia resulting in a platelet count
of ≤ 10,000/microliters for ≥ 5 days

- Able to provide informed consent and comply with treatment and monitoring, or having a
Legally Authorized Representative (LAR)

Exclusion criteria (none can be present):

- Diagnosis of acute promyelocytic leukemia undergoing induction chemotherapy

- History of ITP, TTP or HUS

- Subjects receiving L-asparaginase as part of their current cycle of treatment

- Subjects with a past history or current diagnosis of arterial or venous thromboembolic
disease including acute coronary syndrome, peripheral vascular disease and retinal
arterial or venous thrombosis (except when a prior history of central line thrombosis
has resolved)

- Subjects with a diagnosis/previous history of sinusoidal obstruction syndrome (also
called veno-occlusive disease)

- Subjects receiving any pro-coagulant agents (e.g. DDAVP, recombinant Factor VIIa or
Prothrombin Complex Concentrates (PCC) and/or an antifibrinolytic agent within 48
hours of enrollment, or with known hypercoagulable state

- Known inherited or acquired bleeding disorder including, but not limited to:

- Acquired storage pool deficiency

- Paraproteinemia with platelet inhibition

- Known inherited or acquired prothrombotic disorders, including antiphospholipid
syndrome. Those with lupus anticoagulant or positive antiphospholipid serology without
thrombosis are not excluded.

- Subjects receiving anticoagulant therapy or anti-platelet therapy (except when
receiving prophylactic anticoagulant or low dose aspirin therapy for prophylaxis only
with a plan to discontinue when the platelet count falls below 50,000)

- Patients with DIC according to the patient's physician

- Subjects with WHO Grade 2 bleeding or greater within 48 hours prior to activation

- Subjects requiring a platelet transfusion threshold > 10,000/microliters at time of
randomization

- Subjects with anuria (defined as urine output < 10mls/hr over 24 hours)

- Subjects on dialysis

- Subjects with creatinine ≥5.7mg/dL

- Subjects who are pregnant or nursing or unwilling to use contraception during and for
30 days after taking the study drug (both males and females)

- Subjects enrolled in other trials involving platelet transfusions, anti-fibrinolytics,
platelet growth factors or other pro-coagulant agents.

- Known allergy to tranexamic acid

- Having been previously randomized in this study at any stage of their treatment

- Subjects who are unwilling to accept blood or blood component transfusions
We found this trial at
3
sites
Chapel Hill, North Carolina 27599
(919) 962-2211
Univ of North Carolina Carolina’s vibrant people and programs attest to the University’s long-standing place...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
4200 Fifth Ave
Pittsburgh, Pennsylvania 15260
(412) 624-4141
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Seattle, Washington 98104
(206) 543-2100
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
?
mi
from
Seattle, WA
Click here to add this to my saved trials